Candel therapeutics announces restructuring to prioritize resources on key value drivers for expanded development of can-3110, the enlighten™ discovery platform, and key clinical readouts for can-2409

Needham, mass., nov. 28, 2023 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced a strategic restructuring to focus on continuation and expansion of development of can-3110 as well as the enlighten™ discovery platform, while reducing the company's workforce and expenses associated with enabling commercial readiness of can-2409. the company expects to present initial activity and biomarker data for repeated injections of can-3110 in recurrent high-grade glioma in the second half of 2024 and new data for the second drug candidate based on the enlighten™ discovery platform in q3 2024. the company plans to continue to collect clinical data for key readouts for can-2409 in non-small cell lung cancer (nsclc), with topline overall survival data of the open label phase 2 clinical trial expected in q2 2024; pancreatic cancer, with an update on overall survival based on an interim analysis of the randomized, open label clinical trial in q2 2024; and prostate cancer, with topline data for both fully enrolled randomized, blinded, placebo-controlled phase 2 and phase 3 clinical trials in q4 2024.
CADL Ratings Summary
CADL Quant Ranking